Cytotoxic in Biological Technology

The Breast Cancer Therapeutics Market in Australia

... adverse effects on normal cells when compared to cytotoxic chemotherapeutic drugs. New offerings must ... for chemotherapy. "Due to higher cost compared to cytotoxic and hormonal therapies, the use of targeted ... of these highly specific therapies with existing cytotoxic and hormonal therapies will soon become the ...

Patent for Making Combination Chemotherapy Work Better

... for why today's concurrent HER1 blocker / S-Phase cytotoxic protocols achieve only a fraction of the ... enrichment relative to administrations of S-Phase cytotoxic chemotherapy. "With less than one third of cancer cells in the S-Phase, today's cytotoxic protocols only extend life expectancy by a few ...

AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108

... first drug in a clinical study that targets the cytotoxic activity of doxorubicin specifically to ... of a synthetic peptide carrier and a well-known cytotoxic agent, doxorubicin. The design of this product ... the specific binding and selective uptake of the cytotoxic conjugate by LHRH-receptor-positive tumors. ...

Pharmatek Announces Official Opening of New Highly-Potent & Cytotoxic Development and Manufacturing Facility

... Pharmatek to Serve Growing Highly-Potent and cytotoxic Compound Market SAN ... announced the opening of its highly-potent and cytotoxic facility located in San Diego. The 18,000 sq. ... to the development of highly-potent and cytotoxic drug product for early phase clinical trials. ...

AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers

... first drug in a clinical study that targets the cytotoxic activity of doxorubicin specifically to ... About AEZS-108 AEZS-108 is a targeted cytotoxic peptide conjugate which is a hybrid molecule ... the specific binding and selective uptake of the cytotoxic conjugate by LHRH-receptor-positive tumors. The ...

Viventia Biotech to Explore Strategic Alternatives - Reports Positive Pivotal Phase III Interim Efficacy Data

... cell markers, conjugated to highly potent cytotoxic proteins. Viventia's three lead products target ... a humanized antibody fragment conjugated to the cytotoxic protein Pseudomonas exotoxin A. The drug is in a ... the Company's proprietary deimmunized form of the cytotoxic protein Bouganin, and is designed for systemic ...

AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment

... (formerly ZEN-012) follow-up multi-targeted cytotoxic candidates at the AACR-NCI-EORTC ... The abstract #C218 entitled, "Highly Potent cytotoxic Compounds with Inhibitory Effects on Tubulin ... were equal to or more efficient in exerting cytotoxic activity in tumor cell lines and inhibiting ...

Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory

... Pharmatek Now Offers Contract cytotoxic & High-Potent Analytical, ... Inc. today announced the addition of cytotoxic and high-potent drug development capabilities to ... expansion was driven by an increase in demand for cytotoxic and high-potent drug development and ...

AEterna Zentaris Presents Data Supporting Evaluation of AEZS-108 in Prostate Cancer at ASCO Meeting

... that it presented results supporting the evaluation of its targeted cytotoxic peptide conjugate compound, AEZS-108 (formerly AN-152), in prostate ... the concept of targeting prostatic LHRH receptors to deliver cytotoxic therapy based on LHRH analogs, such as AEZS-108. A copy of the ...

Medarex Announces Allowance of Investigational New Drug Application for Company's First Antibody-Drug Conjugate, MDX-1203

... from its proprietary technology. MDX-1203 is comprised of a potent cytotoxic prodrug chemically linked with a fully human anti-CD70 antibody. CD70 is ... Conjugate platform. Medarex's proprietary ADC technology uses a cytotoxic agent that is a potent, synthetically manufactured prodrug (a DNA ...

A 'Must Read' for Breast Cancer Patients

... cells to enter the S-Phase during the administration time of the S-Phase cytotoxic chemotherapy, and then the road block is reestablished to start aggregating surviving cancer cells for the next administration of S-Phase cytotoxic chemotherapy." The abstract contained in the patent has been incorrectly ...

Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference

... are T cell recruiting antibodies designed to transiently connect cytotoxic T cells with malignant cancer cells, which has been shown to result in the ... represent a new class of antibodies that activate a patient's own cytotoxic T cells to eliminate cancer cells. Micromet is developing MT103 in ...

Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML

... greater; or (iii) a co-morbid condition that precludes them from receiving cytotoxic therapy with cytarabine and an anthracycline. Patients over the age of 70 ... do not confound the results. As Cloretazine(R) (VNP40101M) is a cytotoxic agent which should not be given to healthy volunteers, this evaluation is ...

Sanofi-aventis Announces Second Quarter 2009 Results

... on the results of the AVADO study. First-half net sales of Taxotere((R)) were up 9.5% at euro 1,118 million. Eloxatin ((R)) , the leading cytotoxic agent in the colorectal cancer market as an adjuvant and as a first-line treatment in the metastatic phase, achieved second-quarter growth of 10.0% ...

New Report Just Published: World Prostate Cancer Therapeutics Market Report

... II-47 Chemotherapy II-47 Taxotere(R) (Docetaxel) II-48 Bone Complication Treatments II-48 Bisphosphonate Drugs II-48 Doxazosin, a cytotoxic Drug for Prostate Cancer II-49 Radiation Therapy II-49 Strategies to Enhance Recurrent Prostate Cancer Treatment II-49 Chemotherapy - New ...

CEL-SCI Files Patent Application to Support Company's Treatment for More Virulent Strain of H1N1 Swine and Other Influenza Viruses

... the development of T-cell function with primarily effector T-cell functions (T Lymphocyte; helper/effector T lymphocyte, type 1 or 2 [Th1 or Th2], cytotoxic [Tc] or suppressor [Ts]). The L.E.A.P.S. vaccine constructs are chimeric peptides which combine antigen specificity with immune response modulation. ...

Helix BioPharma to Present L-DOS47 Analytical Method Development Findings at 2009 AAPS National Biotechnology Conference

... As well, the local production of ammonia at the site of cancerous tissues is thought to readily diffuse into the cancer cells to exert a potent cytotoxic effect by interfering with their critical metabolic functions. About Helix BioPharma Corp. Helix BioPharma Corp. is a biopharmaceutical ...

Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia

... p<0.0001) - Well tolerated - short-term mortality substantially lower (13 per cent vs. 25 per cent) Elacytarabine is a novel cytotoxic agent being developed by Clavis Pharma for the treatment of hematologic cancers and solid tumors, especially those resistant to existing agents. One ...

Calvert Research Licenses Novel Technology to Treat Age Related Macular Degeneration from Tulane University

... The preclinical stage compounds licensed by Calvert T1 combine the known anti-proliferative effects of a somatostatin peptide analog with a cytotoxic drug chemically linked to the peptide, resulting in a dual mechanism drug candidate designed to specifically target and kill abnormal blood vessels ...

Celator(R) Pharmaceuticals Presents Data on the Activity of CPX-351 Against Leukemia at the European Hematology Association Congress

... could be detected in the plasma up to Day 12, while remaining bioavailable, led the investigators to conclude that leukemia cells could be exposed to cytotoxic drug levels throughout the first two weeks of induction treatment. In a separate poster presentation, researchers described the results of a ...

Mersana Reports Preliminary Phase 1 Results of XMT-1001 in Patients with Advanced Solid Tumors

... Scottsdale, AZ; Mersana Therapeutics, Inc., Cambridge, MA; Covance Bioanalytical, Madison, WI Session: Developmental Therapeutics: cytotoxic Chemotherapy Type: General Poster Session Time: Saturday May 30, 2009, 8:00 AM to 12:00 PM Location: Level 2, West Hall C About ...

NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS

... the lower density of EGFR in the cells of skin, kidney and gut. In the clinical setting, where the tumor cells rely on the EGFR pathway to repair cytotoxic damage, nimotuzumab reproduces the efficacy of the other EGFR inhibitors in the presence of an astonishingly benign safety profile. The ...

Oral VDA CYT997 - Phase I Clinical Trial Presentation at ASCO

... West Hall C. The poster entitled " P h ase I e val u ation of orally-ad m inistered CYT997, a nov e l cytotoxic vascular- d isrupting agent, in patients with advanced cance r " details safety, tolerability and preliminary activity ...

Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting

... including the Boxed WARNINGS, and for the Medication Guide and Patient Instructions for Use. About Trabectedin Trabectedin is a novel cytotoxic antitumor agent that was originally derived from the Caribbean tunicate, Ecteinascidia turbinate ("sea squirt"). The compound is now produced ...

CEL-SCI Developing Immune-Based Treatment Against Swine and Other H1N1 Flu Viruses Using Proprietary L.E.A.P.S. Technology

... the development of T-cell function with primarily effector T-cell functions (T Lymphocyte; helper/effector T lymphocyte, type 1 or 2 [Th1 or Th2], cytotoxic [Tc] or suppressor [Ts]). The L.E.A.P.S. vaccine constructs are chimeric peptides which combine antigen specificity with immune response modulation. ...

AEterna Zentaris to Present Data Supporting Evaluation of AEZS-108 in Prostate Cancer at Upcoming ASCO Meeting

... a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that results supporting the evaluation of its targeted cytotoxic peptide conjugate compound, AEZS-108, in prostate cancer, will be presented as a poster at the American Society of Clinical Oncology (ASCO) Annual ...

Oncothyreon announces presentations at American Society of Clinical Oncology (ASCO) Annual Meeting

... inhibitor in patients with advanced solid malignancies" - Abstract # 2571, Poster Session: Developmental Therapeutics: cytotoxic Chemotherapy - Saturday May 30, 8:00 AM to 12:00 PM, Level 2, West Hall C About Oncothyreon Oncothyreon is a biotechnology company ...

Successful Phase I/II Clinical Trial Results From Cancer Patients Treated With Anti-Cancer Drug From Axelar AB

... effects during the single-day treatments.", says Johan Harmenberg, CEO of Axelar AB. "Targeting cancer cells with AXL1717 instead of conventional cytotoxic chemotherapy may be a new and well-tolerated treatment alternative for cancer patients in the future." The IGF-1 receptor is a promising ...

Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate

... that neutralize influenza virus and prevent spread throughout the cells of the respiratory tract -- and the matrix 1 or "M1" virus that stimulates cytotoxic T lymphocytes to kill cells that may already be infected. This three-pronged approach may offer an advantage over existing vaccines which contain ...

CEL-SCI's L.E.A.P.S. Technology Shows Potential to Treat Swine Influenza in Preclinical Studies

... the development of T-cell function with primarily effector T-cell functions (T Lymphocyte; helper/effector T lymphocyte, type 1 or 2 [Th1 or Th2], cytotoxic [Tc] or suppressor [Ts]). The L.E.A.P.S. vaccine constructs are chimeric peptides which combine antigen specificity with immune response modulation. ...

CEL-SCI Presents Data at Prestigious Medical Conference Demonstrating That Its L.E.A.P.S. Technology Stimulates Maturation of Human Blood Cells Into Dendritic Cells Suggesting Potential for Prevention and Treatment of Infectious Disease

... the development of T-cell function with primarily effector T-cell functions (T Lymphocyte; helper/effector T lymphocyte, type 1 or 2 [Th1 or Th2], cytotoxic [Tc] or suppressor [Ts]). The L.E.A.P.S. vaccine constructs are chimeric peptides which combine antigen specificity with immune response modulation. ...

AACR 100th Annual Meeting Highlights Superior Ability of InNexus' DXL-Modified Anti-CD20 Antibody to Attach and Kill NHL With Safety Comparable to Approved Antibody Therapies in Preclinical Studies

... activity of the modified anti-CD20 human-mouse chimeric antibody exposed unexpected adverse activity that may not have been seen with the less cytotoxic unmodified antibody. The study determined that the increased target activity and cytotoxicity of DXL-modified anti-CD20 does not affect safety even ...

Cytopia Presentation on VDA CYT997 at AACR Conference

... Phase II clinical studies. Data for CYT997 in a panel of in vitro and in vivo assays will be shown clearly demonstrating the potent antivascular and cytotoxic effects of the compound. About Cytopia Cytopia Ltd is an Australian biotechnology company focused on the discovery and development of new ...

Frost & Sullivan European Drug Discovery Product Innovation Award Bestowed on Xenometrix AG

... inter-assay variability due to differences in cell composition, cellular activity and cell density. "Xenometrix offers testing of chemicals for cytotoxic effects using a range of assays and assay combinations sold as test kits," states Safinia. "The cytotoxicity kits are used by major pharmaceutical, ...

NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus ('RSV') Vaccine Candidate Directed Against the Fusion (F) Protein

... responses observed with either live or inactivated RSV immunization. The VLPs induced strong cell mediated immune responses with activation of CD8+ cytotoxic T-lymphocytes against the F protein, which are important for protection because they kill cells infected with RSV. The RSV-F VLP vaccine candidate ...

First Patient Dosed in Phase 2 Clinical Trial of NKTR-102 in Ovarian Cancer

... NKTR-102. "NKTR-102 is an excellent example of how Nektar's advanced polymer conjugate technology platform allowed us to precisely modify a cytotoxic agent with sub-optimal pharmacokinetics and enhance its therapeutic profile," said Randall Moreadith, M.D., Ph.D., Senior Vice President and Chief ...

Lilly Highlights Transformation Strategy for Wall Street, Reviews Robust Pipeline and Sets 2009 Financial Guidance

... first three quarters of 2008 compared with the same period in 2007. Alimta is now approved in 92 countries and remains the most successfully launched cytotoxic in history, having sold over $3 billion since its introduction in early 2004. Near-term opportunities for Alimta are being pursued in non-small cell ...

Alfacell's ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells

... or R-Amph alone and in combination with the purine analogues cladribine (2-CdA) and fludarabine (FA), as well as with doxorubicin. A significant cytotoxic effect of ONCONASE and R-Amph was evident after 48 and 72 hours of treatment, respectively. Synergistic activity was seen in the combination of the ...

EntreMed Initiates ENMD-2076 Clinical Trial in Multiple Myeloma

... in human cancers. In addition, ENMD-2076 is relatively selective for the Aurora A isoform in comparison to Aurora B. ENMD-2076 has shown significant cytotoxic activity preclinically towards a variety of human leukemia and myeloma cell lines, as well as towards ex vivo-treated human leukemia patient samples. ...

Aposense Receives Frost & Sullivan Technology Innovation of the Year Award

... Aposense technology in pre-clinical development include anticancer therapy which uses apoptotic cells in tumors as targets for specific delivery of cytotoxic compounds into the tumor. For additional information, visit http://www.aposense.com About Frost & Sullivan Frost & Sullivan, the Growth ...